Trial Profile
The Effects of Eicosapentaenoic Acid (EPA) on Biomarkers of Growth and Vascularity in Human Colorectal Cancer Liver Metastases (The EPA for Metastasis Trial)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Eicosapentaenoic acid (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms EMT
- 24 Oct 2012 Safety and biomarker results presented at the 20th United European Gastroenterology Week.
- 31 May 2012 Planned end date changed from 31 Jul 2011 to 1 Aug 2011 as reported by United Kingdom Clinical Research Network record.
- 05 Aug 2011 United Kingdom Clinical Research Network reports accrual date changed from 93% to 100%.